These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 268882)

  • 1. Regional changes of cerebral blood flow during haloperidol therapy in patients with paranoid symptoms.
    Nilsson A; Risberg J; Johanson M; Gustafson L
    Acta Neurol Scand Suppl; 1977; 64():478-9. PubMed ID: 268882
    [No Abstract]   [Full Text] [Related]  

  • 2. [Use of haloperidol in residual schizophrenia and in the paranoid states].
    Jeri FR
    Rev Neuropsiquiatr; 1970 Jun; 33(2):114-22. PubMed ID: 5509272
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical pharmacological studies with haloperidol.
    Dunlop E
    J New Drugs; 1966; 6(4):243-6. PubMed ID: 5968054
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of hostile, suspicious patients. Trifluoperazine versus haloperidol.
    O'Brien CP; DiGiacomo JN; Webb W
    Dis Nerv Syst; 1974 Feb; 35(2):75-8. PubMed ID: 17894044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A therapeutic pathomorphosis of schizophrenia proceeding with paranoid disorders].
    Ozola MIa
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1970; 70(4):600-5. PubMed ID: 5497116
    [No Abstract]   [Full Text] [Related]  

  • 6. Flupenthixol versus haloperidol in acute psychosis.
    Parent M; Toussaint C
    Pharmatherapeutica; 1983; 3(5):354-64. PubMed ID: 6844372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anti-psychotic therapy with haloperidol and clozapine].
    Rüther E
    Fortschr Med; 1979 Aug; 97(32):1372. PubMed ID: 488878
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical and biochemical parameters during neuroleptic treatment. I. Investigations with haloperidol.
    Rüther E; Schilkrut R; Ackenheil M; Eben E; Hippius H
    Pharmakopsychiatr Neuropsychopharmakol; 1976 Jan; 9(1):33-6. PubMed ID: 981320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional cerebral blood flow measurements by 133Xe-inhalation: methodology and applications in neuropsychology and psychiatry.
    Risberg J
    Brain Lang; 1980 Jan; 9(1):9-34. PubMed ID: 7357385
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical and biochemical parameters during neuroleptic treatment. II. Antipsychotic effect of haloperidol in patients with chronic organic brain damage.
    Schilkrut R; Rüther E; Ackenheil M; Eben E; Hippius H
    Pharmakopsychiatr Neuropsychopharmakol; 1976 Jan; 9(1):37-42. PubMed ID: 981321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evaluation in 112 psychiatric patients of a butyrophenone neuroleptic, dehydrobenzperidol (R 4749). A controlled study in 45 patients of dehydrobenzperidol versus haloperidol.
    Cocito E; Ambrosini G; Arata A; Bevilacqua P; Tortora E
    Arzneimittelforschung; 1970 Aug; 20(8):1119-25. PubMed ID: 4921409
    [No Abstract]   [Full Text] [Related]  

  • 12. [On the position of the butyrophenone derivative Haloperidol in psychiatric treatment].
    Greger J; Glitschka A; Müller K
    Psychiatr Neurol Med Psychol (Leipz); 1968 Jun; 20(7):241-52. PubMed ID: 5731879
    [No Abstract]   [Full Text] [Related]  

  • 13. Behavioral prediction of response to haloperidol: a test dose strategy.
    Neborsky R; Janowsky D; Munson E; Hornbeck C; Depry D
    J Clin Psychiatry; 1982 Apr; 43(4):157-8. PubMed ID: 7068547
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of haloperidol and risperidone on cerebrohemodynamics in drug-naive schizophrenic patients.
    Lee SM; Chou YH; Li MH; Wan FJ; Yen MH
    J Psychiatr Res; 2008 Mar; 42(4):328-35. PubMed ID: 17412363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paranoid psychosis after exposure to cyanide.
    Kales SN; Dinklage D; Dickey J; Goldman RH
    Arch Environ Health; 1997; 52(3):245-6. PubMed ID: 9169637
    [No Abstract]   [Full Text] [Related]  

  • 16. Tardive dyskinesia with low-dose, short-term neuroleptic therapy.
    Stimmel GL
    Am J Hosp Pharm; 1976 Sep; 33(9):961-3. PubMed ID: 984060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The connection between psychiatric symptoms and regional cerebral blood flow in presenile dementia].
    Gustafson L
    Lakartidningen; 1974 Mar; 71(13):1287-8. PubMed ID: 4823612
    [No Abstract]   [Full Text] [Related]  

  • 18. Confusional paranoid psychosis after withdrawal from sympathomimetic amines: two case reports.
    Deveaugh-Geiss J; Pandurangi A
    Am J Psychiatry; 1982 Sep; 139(9):1190-1. PubMed ID: 7114316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emotional behaviour, personality changes and cognitive reduction in presenile dementia: related to regional cerebral blood flow.
    Gustafson L; Hagberg B
    Acta Psychiatr Scand Suppl; 1975; 257():37-71. PubMed ID: 1056129
    [No Abstract]   [Full Text] [Related]  

  • 20. Assessment and treatment of drug-induced tremor.
    Goetz CG; Dysken MW; Klawans HL
    J Clin Psychiatry; 1980 Sep; 41(9):310-5. PubMed ID: 7410325
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.